MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/bcp.70566

Медицинская библиотека · British journal of clinical pharmacology · 2026

The interplay of GLP-1 receptor agonist use, chronic kidney disease and fracture risk in obese pAtients: a retrospective cohort study.

Eubanks Amari, Allen Kiana C, Kearney Dy' Quan, Bell Brieanna, Albornoz Anthony, Elkomi Rawan, Ross Damon, Beyene Elizabeth, Bisrat Mekdem, Gillani Syed Fahad, Michael Miriam

СтатьяПеревод в очереди

Аннотация

AIMS: To evaluate the association between Glucagon-like peptide-1 receptor agonist (GLP-1RA) use and fracture risk in patients with or without chronic kidney disease (CKD).

METHODS

A retrospective cohort study was conducted using TriNetX, including patients aged 18-50. Two primary cohorts were defined: obese patients with CKD on GLP-1RAs ≥ 1 year (CKD+/GLP-1RA+) and obese patients with CKD not on GLP-1RAs (CKD+/GLP-1RA-). A subgroup analysis compared CKD+/GLP-1RA + patients to obese patients without CKD on GLP-1RAs (CKD-/GLP-1RA+). Primary outcomes were upper and lower limb fractures. Risk analysis and Kaplan-Meier survival analysis assessed fracture incidence over 5 years.

RESULTS

After matching, 13 441 patients were included per cohort. CKD+/GLP-1RA + patients had fewer fractures than CKD+/GLP-1RA- patients (Risk Difference: -0.016, 95% CI: -0.018, -0.013; RR: 0.196, 95% CI: 0.145, 0.265; OR: 0.193, 95% CI: 0.143, 0.261), with higher fracture-free survival (99.31% vs. 95.47%; p < 0.001). Subgroup analysis (13 723 patients per cohort) showed CKD+/GLP-1RA + patients had a slightly higher fracture risk than CKD-/GLP-1RA + patients (Risk Difference: 0.003, 95% Cl: 0.001, 0.004; RR: 2.357, 95% Cl: 1.516, 3.665; OR: 2.364, 95% Cl: 1.518, 3.680), with lower fracture-free survival (98.87% vs. 99.19%; p < 0.001).

CONCLUSION

These findings suggest a possible CKD-associated modification on the skeletal effects of GLP-1RAs, implicating that CKD patients' bone health should be monitored during GLP-1RA treatment.

Для цитирования: Eubanks Amari, Allen Kiana C, Kearney Dy' Quan, Bell Brieanna, Albornoz Anthony, Elkomi Rawan, Ross Damon, Beyene Elizabeth, Bisrat Mekdem, Gillani Syed Fahad, Michael Miriam. The interplay of GLP-1 receptor agonist use, chronic kidney disease and fracture risk in obese pAtients: a retrospective cohort study.. British journal of clinical pharmacology. 2026. DOI: 10.1002/bcp.70566.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.